ArticleHemaSphere2020

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.

Georg Hess et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.